Genetically knocking down ELK1 by shRNA or pharmacologically inhibiting ELK1 by TDE reduces amyloidogenic cleavage of APP, thereby inhibiting senile plaque formation and improving synaptic and cognitive deficits in APP23/PS45 double-transgenic AD model mice (Figs. 4 and 6). This evidence concerns the gene APP and Alzheimer disease.